Core Insights - Motorola (MSI) is expected to report quarterly earnings of $3.01 per share, reflecting a 7.1% increase year-over-year, with revenues projected at $2.51 billion, a 5.3% increase from the previous year [1] - Analysts have revised their consensus EPS estimate upward by 0.1% over the past 30 days, indicating a collective reassessment of projections [1][2] Revenue Projections - Analysts forecast 'Net sales- Products and Systems Integration' to reach $1.54 billion, indicating a year-over-year change of +3.2% [4] - 'Net sales- Software and Services' are projected to be $976.40 million, reflecting an increase of +8.6% from the prior-year quarter [4] - 'Net sales from products' are expected to be $1.48 billion, showing a change of +5.1% from the previous year [4] Earnings Estimates - 'Net sales from services' are anticipated to reach $1.04 billion, indicating a +5.4% change from the year-ago quarter [5] - 'Non-GAAP Operating Earnings- Software and Services Segment' is projected at $265.27 million, slightly down from $268 million in the previous year [5] - 'Non-GAAP Operating Earnings- Products and Systems Integration Segment' is expected to be $408.69 million, up from $370 million reported in the same quarter last year [6] Stock Performance - Over the past month, Motorola shares have returned -0.6%, compared to a -4.3% change in the Zacks S&P 500 composite [7] - Currently, MSI holds a Zacks Rank 3 (Hold), suggesting its performance may align with the overall market in the near future [7]

Core Viewpoint - Analysts project that Duolingo, Inc. (DUOL) will report quarterly earnings of $0.52 per share, reflecting an 8.8% decline year over year, while revenues are expected to reach $223.33 million, marking a 33.3% increase from the same quarter last year [1] Earnings Projections - The consensus EPS estimate for the quarter has been revised upward by 2.9% over the past 30 days, indicating a collective reassessment by analysts [2] - It is crucial to consider revisions to earnings projections prior to a company's earnings release, as they are a strong indicator of potential investor behavior [3] Revenue Estimates - Analysts forecast 'Revenues- Subscription' to reach $187.35 million, indicating a year-over-year increase of 42.3% [5] - 'Revenues- Other- Duolingo English Test' is projected to be $12.59 million, suggesting a decline of 1.3% year over year [5] - 'Revenues- Other- Advertising' is expected to reach $14.16 million, reflecting a 9.3% increase from the previous year [5] Bookings and User Metrics - The consensus estimate for 'Total bookings' is $255.18 million, compared to $197.45 million in the same quarter last year [6] - 'Subscription bookings' are projected to be $219.26 million, up from $161.47 million year over year [6] - Analysts estimate 'Daily active users (DAUs)' will reach 46.00 million, an increase from 31.4 million in the same quarter last year [6] Active User Projections - The estimated 'Monthly active users (MAUs)' is 120.45 million, compared to 97.6 million in the same quarter last year [7] - 'Paid subscribers (at period end)' are projected to reach 10.47 million, up from 7.4 million year over year [7] Stock Performance - Over the past month, Duolingo shares have returned +21.2%, contrasting with a -4.3% change in the Zacks S&P 500 composite [8] - Currently, DUOL holds a Zacks Rank 3 (Hold), suggesting its performance may align with the overall market in the near future [8]

According to the collective judgment of analysts, 'Revenues- Imaging' should come in at $2.03 billion. The estimate indicates a year-over-year change of -17.8%. Based on the collective assessment of analysts, 'Revenues- Ultrasound' should arrive at $1.22 billion. The estimate suggests a change of +48.5% year over year. Analysts on Wall Street project that GE HealthCare Technologies (GEHC) will announce quarterly earnings of $0.91 per share in its forthcoming report, representing an increase of 1.1% year ove ...

Core Insights - Analysts project Pebblebrook Hotel (PEB) will report quarterly earnings of $0.13 per share, a decline of 38.1% year over year, with revenues expected to reach $317.88 million, reflecting a 1.2% increase from the same quarter last year [1] Earnings Estimates - The consensus EPS estimate for the quarter has been adjusted upward by 0.9% over the past 30 days, indicating a reassessment by covering analysts [2] - Revisions to earnings projections are crucial for predicting investor behavior, as empirical studies show a strong correlation between earnings estimate trends and short-term stock performance [3] Revenue Projections - Analysts estimate 'Revenue- Food and beverage' at $83.15 million, a 2.5% increase year over year [5] - 'Revenue- Other operating' is projected at $36.15 million, suggesting a 3.7% year-over-year change [5] - The consensus estimate for 'Revenue- Room' stands at $198.58 million, indicating a 0.2% increase from the previous year [5] Operational Metrics - The estimated 'Total Guest Rooms' is 11,797, down from 12,000 year over year [6] - Analysts predict 'Depreciation and amortization' will be $55.28 million, compared to $57.21 million from the previous year [6] Stock Performance - Over the past month, Pebblebrook Hotel shares have declined by 9.8%, while the Zacks S&P 500 composite has decreased by 4.3% [7] - Pebblebrook Hotel holds a Zacks Rank 3 (Hold), suggesting its performance will likely align with the overall market in the near term [7]

While investors typically use consensus earnings and revenue estimates as a yardstick to evaluate the company's quarterly performance, scrutinizing analysts' projections for some of the company's key metrics can offer a more comprehensive perspective. Bearing this in mind, let's now explore the average estimates of specific Airbnb metrics that are commonly monitored and projected by Wall Street analysts. The consensus estimate for 'Gross Booking Value' stands at $24.62 billion. The estimate is in contrast t ...

Core Insights - MetLife (MET) is expected to report quarterly earnings of $1.99 per share, reflecting an 8.7% increase year-over-year, with revenues projected at $18.21 billion, a 7% increase from the previous year [1]. Earnings Projections - The consensus EPS estimate has been revised down by 2.7% in the last 30 days, indicating a reassessment by analysts [2]. - Changes in earnings projections are crucial for predicting investor reactions, as empirical studies show a strong correlation between earnings estimate trends and short-term stock price movements [3]. Revenue Estimates - Analysts project 'Revenue- Premiums' to reach $10.97 billion, indicating a year-over-year increase of 9.1% [5]. - 'Revenue- Other Revenues' is expected to be $631.98 million, reflecting a decline of 6.2% year-over-year [5]. - 'Revenue- Universal life and investment-type product policy fees' is forecasted at $1.27 billion, showing a 1.7% increase from the prior year [5]. Investment Income and Regional Revenue - 'Revenue- Net investment income' is estimated at $5.27 billion, suggesting a decrease of 3.1% year-over-year [6]. - 'Total Adjusted Revenue- Latin America' is projected to be $1.95 billion, indicating a 3.4% increase year-over-year [6]. - 'Total Adjusted Revenue- U.S. Business' is expected to reach $10.64 billion, reflecting an 11.5% increase year-over-year [7]. Regional Adjusted Revenue - 'Total Adjusted Revenue- EMEA' is estimated at $703.80 million, indicating a 4.4% increase year-over-year [8]. - 'Total Adjusted Revenue- Asia' is projected to be $2.99 billion, reflecting a 4.8% increase year-over-year [8]. - 'Adjusted Revenue- Asia- Net investment income' is expected to reach $1.25 billion, indicating a 13% increase from the prior year [9]. Stock Performance - MetLife shares have decreased by 8.7% over the past month, compared to a 4.8% decline in the Zacks S&P 500 composite [10].

Wall Street analysts forecast that Microsoft (MSFT) will report quarterly earnings of $3.20 per share in its upcoming release, pointing to a year-over-year increase of 8.8%. It is anticipated that revenues will amount to $68.38 billion, exhibiting an increase of 10.6% compared to the year-ago quarter.The consensus EPS estimate for the quarter has undergone a downward revision of 1% in the past 30 days, bringing it to its present level. This represents how the covering analysts, as a whole, have reassessed t ...

Core Insights - Analysts forecast that Paypal (PYPL) will report quarterly earnings of $1.15 per share, reflecting a year-over-year decline of 17.9%, with revenues expected to reach $7.83 billion, an increase of 1.6% compared to the previous year [1] Earnings Projections - Over the past 30 days, the consensus EPS estimate has been adjusted downward by 0.9%, indicating a reassessment of initial projections by covering analysts [2] - Changes in earnings projections are crucial for predicting investor reactions, as empirical studies show a strong correlation between earnings estimate trends and short-term stock price movements [3] Revenue and Key Metrics - Analysts estimate that 'Revenues from other value added services' will be $667.22 million, a change of +0.3% from the prior year [5] - 'Transaction revenues' are projected to reach $7.17 billion, indicating a year-over-year change of +1.9% [5] - 'Total Payment Volume (TPV)' is expected to arrive at $420.67 billion, up from $403.86 billion in the same quarter last year [6] - The 'Transaction margin' is predicted to be 46.5%, compared to 45% in the same quarter of the previous year [6] - Analysts forecast 'Active accounts' to reach 435, up from 427 a year ago [6] - The 'Number of payment transactions' is expected to be 6,676, compared to 6,505 in the previous year [7] Market Performance - Shares of Paypal have decreased by 10.7% in the past month, contrasting with a 5.1% decline in the Zacks S&P 500 composite [7] - With a Zacks Rank 3 (Hold), PYPL is anticipated to reflect overall market performance in the near future [7]

Core Insights - Astrazeneca (AZN) is projected to report quarterly earnings of $1.10 per share, a 6.8% increase year-over-year, with revenues expected to reach $13.68 billion, reflecting a 7.9% year-over-year growth [1] Earnings Projections - There have been no revisions in the consensus EPS estimate for the quarter over the last 30 days, indicating stability in analysts' forecasts [1] - Changes in earnings projections are crucial for predicting investor reactions, as empirical studies show a strong correlation between earnings estimate trends and short-term stock price movements [2] Key Metrics Estimates - Analysts predict 'BioPharmaceuticals- CVRM- Crestor- World' will reach $294.03 million, a -1% change year-over-year [4] - The estimate for 'BioPharmaceuticals- CVRM- Seloken/Toprol-XL- World' is $154.45 million, indicating a -6.4% change [4] - 'Oncology- Zoladex- World' is estimated at $268.24 million, reflecting a -2.8% change [4] Additional Product Estimates - 'Oncology- Tagrisso- World' is expected to reach $1.67 billion, a +4.6% change year-over-year [5] - The consensus for 'BioPharmaceuticals- CVRM- Crestor- U.S.' stands at $8.31 million, indicating a -16.9% change [5] - 'Other Medicines- Nexium- U.S.' is projected at $19.28 million, suggesting a -12.4% change [5] Further Product Insights - 'BioPharmaceuticals- R&I- Fasenra- U.S.' is forecasted to reach $220.22 million, a +4.9% change [6] - 'BioPharmaceuticals- CVRM- Brilinta- U.S.' is estimated at $133.59 million, indicating an -18% change [6] - 'Oncology- Lynparza- U.S.' is projected at $302.67 million, reflecting a +5.1% change [6] Oncology Product Forecasts - 'Oncology- Imfinzi- U.S.' is expected to come in at $719.14 million, a +23.6% change year-over-year [7] - 'Oncology- Calquence- U.S.' is projected at $493.39 million, indicating a -0.1% change [7] - 'BioPharmaceuticals- CVRM- Farxiga- U.S.' is estimated to reach $489.15 million, reflecting a +3% change [7] Stock Performance - Astrazeneca shares have decreased by -5.8% over the past month, compared to a -5.1% change in the Zacks S&P 500 composite [8] - With a Zacks Rank 3 (Hold), AZN is expected to perform in line with the overall market in the near future [8]

Core Viewpoint - Alexandria Real Estate Equities (ARE) is expected to report a decline in quarterly earnings and revenues, indicating a challenging financial outlook for the company [1][2]. Financial Projections - Analysts predict quarterly earnings of $2.28 per share, reflecting a 3% decline year-over-year [1]. - Revenues are forecasted to be $758.46 million, representing a year-over-year decrease of 1.4% [1]. - The consensus EPS estimate has been revised downward by 0.1% over the past 30 days, indicating a reappraisal of projections by analysts [2]. Key Metrics Analysis - 'Revenues- Other income' is projected to reach $16.66 million, showing a year-over-year increase of 22.9% [5]. - 'Revenues- Rental' is expected to be $749.38 million, suggesting a year-over-year decrease of 0.8% [5]. - The average prediction for 'Depreciation and amortization' is $318.88 million, compared to $287.55 million reported in the same quarter last year [5]. Market Performance - Alexandria Real Estate Equities shares have decreased by 20.6% in the past month, contrasting with the Zacks S&P 500 composite's decline of 6.6% [6]. - The company holds a Zacks Rank 4 (Sell), indicating expectations of underperformance relative to the overall market in the near term [6].